The use of mirabegron in neurogenic bladder: a systematic review

Helou, Elie El; Labaki, Chris; Chebel, Roy; Hélou, Josiane; Tayeh, Georges Abi; Jalkh, Georges; Nemr, Elie

doi:10.1007/s00345-019-03040-x

Cited by 29 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of our experiments suggest that systemically administered β 3 ‐adrenergic receptor agonists might act directly on the bladder. This might further indicate the potential for β 3 ‐adrenoceptor agonists as effective agents for universal OAB, regardless of the presence or level of neurological deficits, by acting directly on the bladder even for OAB that is refractory to anticholinergics 25 …”

Section: Discussionmentioning

confidence: 99%

“…The clinical effectiveness of β 3 ‐adrenoceptor agonists on neurogenic detrusor overactivity has not yet been fully approved 25 because the pharmacological mechanism is still equivocal, and there is limited clinical experience using β3‐adrenoceptor agonists to treat neurogenic detrusor overactivity. The results of our experiments suggest that systemically administered β 3 ‐adrenergic receptor agonists might act directly on the bladder.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of β3‐adrenoceptor agonist on the micromotion of bilateral major pelvic ganglion‐excised rat bladder

Son

Moon

Kwon

et al. 2023

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims: Micromotion is an autonomous intramural movement of the bladder, and is believed to be an initial step in the generation of urinary urgency. Therefore, controlling micromotion may be a novel target in overactive bladder (OAB) treatment. However, developing micromotion treatment has been limited by the absence of a standardized animal model. We attempted to create a micromotion animal model and investigated the effectiveness of a β 3 -adrenoceptor agonist (CL316,243) on micromotion. Methods: Bilateral major pelvic ganglia (MPGs) were excised in 18 male Sprague-Dawley rats, resulting in an almost completely denervated bladder.On postoperative Day 7, cystometry was performed. Rats were divided into three treatment groups: CL316,243; β 3-adrenoceptor antagonist (SR59230A) pretreated CL316,243; and a nonselective antimuscarinic agent (oxybutynin). Changes in micromotion were evaluated after the intra-arterial administration of each agent. Results: Low-amplitude oscillations in intravesical pressure (micromotion) were observed 1 week after MPGs excision. Micromotion frequency significantly (p = 0.003) decreased (2.17 ± 3.54 times/5 min) with CL316,243 compared with vehicle (6.33 ± 1.97 times/5 min). Micromotion amplitude also decreased with CL316,243 (1.15 ± 1.93 cmH 2 O) compared with vehicle (5.96 ± 5.12 cmH 2 O), approaching conventional significance (p = 0.090). No significant decreases in frequency or amplitude were observed with oxybutynin treatment.Conclusions: Systemic administration of the β 3 -adrenoceptor agonist CL316,243 effectively controlled micromotion in bilateral MPGs-excised, almost completely denervated rat bladders. This result indicates that β 3 -adrenoceptor agonist may affect the bladder directly, suggesting that it might be effective for overall OAB, regardless of the presence or level of neurological deficits. Bilateral MPGs-excised rats are considered a plausible micromotion animal model suitable for future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effect of β3‐adrenoceptor agonist on the micromotion of bilateral major pelvic ganglion‐excised rat bladder

Son

Moon

Kwon

et al. 2023

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…However, there is still no evidence concerning the use of mirabegron as a first‐line therapy for neurogenic bladder. 14 …”

Section: Discussionmentioning

confidence: 99%

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series

et al. 2021

View full text Add to dashboard Cite

Introduction Neurogenic overactive bladder is a main feature of human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis. We successfully performed intravesical onabotulinumtoxinA therapy for refractory neurogenic overactive bladder due to human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis. Case presentation We retrospectively reviewed four neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis who underwent bladder wall injections of onabotulinumtoxinA from April to October 2020. All patients were female. Their median age was 66 (range, 63–71) years. They were previously treated with β3‐adrenergic receptor agonists or anticholinergic drugs alone or in combination for ≥12 weeks. However, insufficient results were obtained. After 4 weeks of intravesical onabotulinumtoxinA therapy, overactive bladder symptoms improved and maximum cystometric capacity increased in all cases. Conclusion Intravesical onabotulinumtoxinA therapy may be useful for treating refractory overactive bladder due to human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis.

show abstract

“…Recently, in a systematic review of the efficacy and safety of mirabegron for neurogenic bladder dysfunction, El Helou et al reported that mirabegron was also effective and safe for subjective symptoms and objective findings, such as urodynamic studies. 4 However, patients in all the studies cited in this article received mirabegron in anticholinergic refractory cases, and to the best of our knowledge, there is no detailed study on the efficacy of b3-adrenergic receptor agonists as a first-line drug in patients with neurogenic bladder dysfunction. Therefore, prospective studies on b3-adrenergic receptor agonists are warranted in the future for the selection of treatments for neurogenic bladder dysfunction.…”

Section: Editorial Comment Editorial Commentmentioning

confidence: 99%

Editorial Comment to Video‐urodynamic effects of vibegron, a new selective β3‐adrenoceptor agonist, on antimuscarinic‐resistant neurogenic bladder dysfunction in patients with spina bifida

2021

View full text Add to dashboard Cite

show abstract

The use of mirabegron in neurogenic bladder: a systematic review

Cited by 29 publications

References 20 publications

Effect of β3‐adrenoceptor agonist on the micromotion of bilateral major pelvic ganglion‐excised rat bladder

Effect of β3‐adrenoceptor agonist on the micromotion of bilateral major pelvic ganglion‐excised rat bladder

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series

Editorial Comment to Video‐urodynamic effects of vibegron, a new selective β3‐adrenoceptor agonist, on antimuscarinic‐resistant neurogenic bladder dysfunction in patients with spina bifida

Contact Info

Product

Resources

About